Clinical predictors of response to cetuximab-chemotherapy in metastatic colorectal cancer.
Clinical predictors of response to cetuximab-chemotherapy in metastatic colorectal cancer.
复制标题
转移性结直肠癌西妥昔单抗化疗反应的临床预测因子。
DOI：
--
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
A. Chan
中科院分区：
文献类型：
--
作者：
A. T. Ma;B. Ma;K. Lei;F. Mo;A. Chan
OBJECTIVE
To identify clinical markers to predict which patients with advanced colorectal cancers are likely to benefit from cetuximab-chemotherapy.
DESIGN
Retrospective review.
SETTING
Oncology unit in a university teaching hospital in Hong Kong.
PATIENTS
A total of 102 patients with metastatic colorectal cancer treated with cetuximab-chemotherapy.
MAIN OUTCOME MEASURES
Correlation of multiple potential clinical predictive factors with tumour response to cetuximab-chemotherapy.
RESULTS
The objective response rates to cetuximab plus chemotherapy were 53% in patients receiving first-line treatment and 17% in previously treated patients. The univariate analysis indicated that fewer prior lines of chemotherapy (odds ratio=0.36; 95% confidence interval, 0.21-0.63; P<0.01) and development of cetuximab-related grade 3 rash (5.52; 1.62-18.76; P<0.01) were associated with significantly higher response rates. Multivariate analysis confirmed the independent predictive value of the number of prior chemotherapy regimens (odds ratio=0.37; 95% confidence interval, 0.20-0.69; P<0.01) and grade 3 rash (4.65; 1.21-19.29; P=0.03).
CONCLUSIONS
In this cohort of Chinese patients with advanced colorectal cancer, the presence of grade 3 rash and the number of prior chemotherapy regimens were independent predictors of response to cetuximab-chemotherapy. The utility of these clinical markers in clinical practice should be further evaluated together with established biomarkers.
影响因子：
9
作者：
Fong, Y;Fortner, J;Blumgart, LH
通讯作者：
Blumgart, LH
影响因子：
45.3
作者：
Goldberg, RM;Sargent, DJ;Alberts, SR
通讯作者：
Alberts, SR